Sign In
Last checked at 
9 Apr 2015 11:16
Hikma Pharmaceuticals PLC
Annual Information Update
London, 9 April 2015. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the period. In accordance with Prospectus Rule 5.2.7, it is acknowledged that whilst the information referred to in this update was up to date at the time of publication, such disclosures may, at any time, become out of date due to changing circumstances.
Stock Exchange Announcements
Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/). The Stock Exchange announcements made during the period were:
Date | Headline |
09/04/2015 | Annual Financial Report |
01/04/2015 | Hikma Prices debut $500 million five-year eurobond |
31/03/2015 | Stabilisation Notice |
19/03/2015 | Fixed income investor meetings |
13/03/2015 | Director/PDMR Shareholding |
11/03/2015 | Holding(s) in Company |
11/03/2015 | Final Results |
23/01/2015 | Director Declaration |
21/01/2015 | Notification of major interest in shares |
15/01/2015 | Blocklisting Interim Review |
12/01/2015 | Hikma to launch colchicine 0.6mg capsules |
07/01/2015 | Total Voting Rights |
12/11/2014 | Director/PDMR Shareholding |
11/11/2014 | Total Voting Rights |
07/11/2014 | Notification of major interest in shares |
06/11/2014 | Directorate Change |
06/11/2014 | Interim Management Statement |
24/10/2014 | Hikma announces receipt of Warning Letter from FDA |
20/10/2014 | Director/PDMR Shareholding |
10/10/2014 | Statement re Colchicine |
10/10/2014 | Director/PDMR Shareholding |
06/10/2014 | Blocklisting Interim Review |
06/10/2014 | Total Voting Rights |
30/09/2014 | Regulatory Approval Colchicine |
17/09/2014 | Acquisition |
20/08/2014 | Dividend Declaration |
20/08/2014 | Interim Results |
07/08/2014 | Notice of Interim Results Announcement |
28/07/2014 | Director/PDMR Shareholding |
24/07/2014 | Acquisition |
15/07/2014 | Acquisition |
14/07/2014 | Total Voting Rights |
27/06/2014 | Director/PDMR Shareholding |
23/06/2014 | Director/PDMR Shareholding |
11/06/2014 | Director/PDMR Shareholding |
10/06/2014 | Total Voting Rights |
29/05/2014 | Director/PDMR Shareholding |
29/05/2014 | Director/PDMR Shareholding |
28/05/2014 | Acquisition |
27/05/2014 | Director/PDMR Shareholding |
15/05/2014 | Results of AGM |
15/04/2014 | Interim Management Statement |
06/05/2014 | Director/PDMR Shareholding |
17/04/2014 | Annual Information Update |
All of the above announcements were also made by the Company via the Nasdaq Dubai stock exchange CANDI system. These announcements may be viewed and downloaded from the Nasdaq Dubai website (www.candi.nasdaq.com).
Documents filed with the Financial Services Authority
The Company has filed the following documents with the Financial Services Authority ("FSA") visa the National Storage Mechanism over the previous 12 months. These documents are available at http://www.hemscott.com/nsm.do or at the Company's registered office.
Date | Document |
09/04/2015 | Annual Report and Accounts 2014 |
09/04/2015 | Notice of 2015 Annual General Meeting |
09/04/2015 | Proxy forms for the 2015 Annual General Meeting |
10/04/2014 | Annual Report and Accounts 2013 |
10/04/2014 | Notice of 2014 Annual General Meeting |
10/04/2014 | Proxy forms for the 2014 Annual General Meeting |
Documents filed with Companies House
The Company submitted filings to the Registrar of Companies in England and Wales as detailed in the table below.
Date Filed | Form | Description |
07/04/2015 | SH01 | Statement of Capital GBP 19,887,933.90 |
12/12/2014 | AP01 | Director Appointed Dr. Pamela Josephine Kirby |
11/11/2014 | SH01 | Statement of Capital GBP 19,862,523.90 |
06/10/2014 | SH01 | Statement of Capital GBP 19,855,195 |
08/09/2014 | AR01 | No Member List |
10/06/2014 | SH01 | Statement of Capital GBP 19,843,04.77 |
09/06/2014 | RES01 | Alter Articles 15/05/2014 |
09/06/2014 | MEM/ARTS | Articles of Association |
21/05/2014 | SH04 | Treasury Capital GBP 0 |
20/05/2014 | RES01 | Alter Articles 15/05/2014 |
20/05/2014 | AA | Group of Companies' Accounts made up to 31/12/13 |
15/05/2014 | AP01 | Director Appointed Mr. Patrick Noel Butler |
15/05/2014 | TM01 | Appointment Terminated, Director Samih Darwazah |
15/05/2014 | TM01 | Appointment Terminated, Director David Rowe Ham |
23/04/2014 | MR01 | Registration of a Charge/ Charge Code 055579340003 |
07/04/2014 | SH01 | Statement of Capital GBP 19,815,699.70 |
Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House "Webcheck" at www.companieshouse.gov.uk.
Documents provided to Shareholders
Further Information
Copies of all documents can be obtained from the Company at the registered office which is located at 13 Hanover Square, London W1S 1HW.
Peter Speirs
Company Secretary9 April 2015
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC | |
Peter Speirs Company Secretary
| +44 20 7399 2670 |
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $299 million.
Follow the stocks
